entertainment -WSS

entertainment

author：entertainment 2025-10-01 01:50:11 - browse：5937

The New York Stock Exchange (NYSE) — Spencer Platt/Getty Images

Biohaven Pharmaceuticals said Wednesday that a new type of experimental medicine reduced levels of a disease-causing immune molecule by up to 37% in an early-stage study of human volunteers — a result that the company called “positive” as a proof of concept but that also fell short of investor expectations.

The drug, called BHV-1300, belongs to a new class of antibody medicines that shuttle harmful proteins to the liver so they can be removed from the body. BHV-1300 is specifically designed to reduce levels of an autoantibody called IgG that is implicated in rheumatoid arthritis, myasthenia gravis, and other autoimmune disorders.

In its Phase 1 study, Biohaven tested four escalating doses of BHV-1300 in healthy volunteers, showing a reduction in levels of IgG of 5%, 15%, 30%, and 37%, respectively, the company said. The reductions in IgG levels, which occurred relatively quickly in just four to five days, did not cause significant, adverse changes in liver enzyme levels, Biohaven added — an important safety check given the mechanism of the drug.

STAT+ Exclusive Story

Already have an account? Log in

This article is exclusive to STAT+ subscribers

Unlock this article — plus daily coverage and analysis of the biotech sector — by subscribing to STAT+.

Already have an account? Log in

Monthly

$39

Totals $468 per year

$39/month Get Started

Totals $468 per year

Starter

$30

for 3 months, then $39/month

$30 for 3 months Get Started

Then $39/month

Annual

$399

Save 15%

$399/year Get Started

Save 15%

11+ Users

Custom

Savings start at 25%!

Request A Quote Request A Quote

Savings start at 25%!

2-10 Users

$300

Annually per user

$300/year Get Started

$300 Annually per user

View All Plans

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Affirmative action in medical school literally saved lives
Next article： A single drug, study failures leave Anavex with nothing but cash

focus

WSS

Susan Tousi leaves Illumina to head cancer liquid biopsy startup

H.R. 3 is the wrong path to lower drug costs

A single drug, study failures leave Anavex with nothing but cash

The biotech scorecard for Q1: 17 stock

How a scoliosis diagnosis changed the life of one young dancer

FAA sets up new process for Hawaii air tour operators to fly at lower altitudes after fatal crashes

entertainment

entertainment

This article is exclusive to STAT+ subscribers

Unlock this article — plus daily coverage and analysis of the biotech sector — by subscribing to STAT+.

leisure time

Duchenne breakthrough therapy leaves behind pioneering families

UCB departs biotech trade group BIO

Trump demands the U.S. pay no more for drugs than other countries … again

Listen: Biotech layoffs, eye drug drama, & gene therapy milestones

Duchenne breakthrough therapy leaves behind pioneering families

Ahead of JPM, here's who's profiting most in health care

The high cost of giving birth even with insurance

J&J to buy cancer drug developer Ambrx Biopharma

Guidelines to prevent youth baseball injuries need more muscle

Biotech startup Celsius cuts 75% of staff ahead of first trial start

focus

Late stage cancers on the rise after pandemic delayed screenings

'Null' research findings aren't empty of meaning. Let's publish them

Goldman Sachs launches $650M fund for life science investments

Chris Christie meets with Zelenskyy during Ukraine trip

Feng Zhang CRISPR delivery startup lays off quarter of staff

CDC recommends RSV monoclonal antibody for infants

knowledge

knowledge

focus

knowledge